TIDMIPO
IP Group PLC
22 May 2020
FOR RELEASE ON 22 May 2020
IP Group plc - Portfolio company Oxford Nanopore Technologies
announces advanced development of LamPORE, for rapid, highly
scalable, low-cost COVID-19 detection
IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the
Company"), the developer of intellectual property-based businesses,
notes that its portfolio company Oxford Nanopore Technologies
Limited ("Oxford Nanopore"), has announced that it is in advanced
development of a new generation of end-to-end test (assay) for the
detection of SARS-CoV-2, the virus that causes COVID-19.
The LamPORE assay is designed to be rapid, low cost, and
scalable to cater to on-demand analysis of smaller sample numbers,
to very large numbers of samples. LamPORE is based on Oxford
Nanopore's DNA/RNA sequencing technology, in combination with a
simple, sample-preparation method (loop-mediated isothermal
amplification, plus Oxford Nanopore's 'rapid kit'). It seeks to
understand whether a sample currently contains SARS-CoV-2 (rather
than detecting antibodies that may indicate a previous
infection).
LamPORE is the first assay that the Company has developed
in-house with intended use in diagnostic applications, subject to
relevant authorisations that the Company is currently pursuing.
Oxford Nanopore is planning to deploy LamPORE for COVID-19 in a
regulated setting initially on GridION and soon after on the
portable MinION Mk1C.
IP Group holds an undiluted beneficial stake of 16.4% in Oxford
Nanopore.
Alan Aubrey, Chief Executive of IP Group , said: "Oxford
Nanopore has been supplying countries all over the world with
sequencing capability throughout this pandemic and it's exciting to
see the first diagnostic assay developed in-house, using their
expertise, technology and networks to help support the response to
this crisis."
Since the first emergence of the virus, Oxford Nanopore's rapid,
portable sequencing technology has been used extensively for
COVID-19 epidemiology and scientific research.
The full announcement follows.
For more information, please contact:
IP Group plc www.ipgroupplc.com
+44 (0) 20 7444 0050
Greg Smith, Chief Financial Officer +44 (0) 20 7444 0062/+44 (0)
Liz Vaughan-Adams, Communications 7979 853802
Charlotte Street Partners
David Gaffney +44 (0) 7854 609998
Andrew Wilson +44 (0) 7810 636995
Notes for editors
About IP Group
IP Group is a leading intellectual property commercialisation
company which focuses on evolving great ideas, mainly from its
partner universities, into world-changing businesses. The Group has
pioneered a unique approach to developing these ideas and the
resulting businesses by providing access to business building
expertise, capital (through its 100%-owned FCA-authorised
subsidiaries IP Capital and Parkwalk Advisors), networks,
recruitment and business support. IP Group has a strong track
record of success and its portfolio comprises holdings in
early-stage to mature businesses across life sciences and
technology. IP Group is listed on the Main Market of the London
Stock Exchange under the code IPO.
For more information, please visit our website at
www.ipgroupplc.com .
ENDS
Oxford Nanopore Technologies announces advanced development of
LamPORE, for rapid, highly scalable, low-cost COVID-19
detection
-LamPORE is designed for use in both high-throughput labs or
decentralised locations-
Oxford, UK, 22 May 2020. Oxford Nanopore Technologies is in
advanced development of a new generation of end-to-end test (assay)
for the detection of SARS-CoV-2, the virus that causes
COVID-19.
The LamPORE assay is designed to be rapid, low cost, and
scalable to cater to on-demand analysis of smaller sample numbers,
to very large numbers of samples. Hardware and reagents sit outside
current, squeezed supply chains for other molecular tests.
LamPORE is based on Oxford Nanopore's DNA/RNA sequencing
technology, in combination with a simple, sample-preparation method
(loop-mediated isothermal amplification, plus Oxford Nanopore's
'rapid kit'). It seeks to understand whether a sample currently
contains SARS-CoV-2 (rather than detecting antibodies that may
indicate a previous infection).
Since the first emergence of the virus, Oxford Nanopore's rapid,
portable sequencing technology has been used extensively for
COVID-19 epidemiology and scientific research .
LamPORE is the first assay that the Company has developed
in-house with intended use in diagnostic applications, subject to
relevant authorisations that the Company is currently pursuing.
Oxford Nanopore is planning to deploy LamPORE for COVID-19 in a
regulated setting initially on GridION and soon after on the
portable MinION Mk1C.
The LamPORE protocol will also be made openly available for
research use on any Oxford Nanopore device.
Oxford Nanopore's vision is to support wide efforts to identify,
track, trace and isolate cases. LamPORE is designed to enable rapid
detection of SARS-CoV-2, whether in a high-throughput centralised
lab processing thousands of samples, or for on-demand analysis in
decentralised locations, so that analysis can be performed in more
community settings.
LamPORE is designed to enable:
-- Very high throughput, centralised lab-based analyses: for
example, to support routine screening of workforces - whether on
the frontline or to support a general return to work. This might
include regular screening of healthcare workers/other public sector
employees, or businesses' employees, whether symptomatic or
asymptomatic.
-- Near-community : Also designed to be deployable in
decentralised environments, LamPORE opens up potential
opportunities for rapid, local testing as restrictions are eased,
for example in care homes, transport networks, businesses or other
community settings. Decentralisation supports rapid turnaround of
testing, which is important to enable rapid, precise isolation and
therefore prevent onwards transmission of the virus.
The LamPORE method can also be used to analyse environmental
samples to assess for the presence of the SARS-CoV-2 virus. This
has the potential to be used for swabbing surfaces, or systems such
as water treatment.
LamPORE does not rely on reagents used in traditional COVID-19
tests, which could ease pressure on current supply chains and
expand access.
"This year we have gained extensive experience supporting
customers using our sequencing technology for COVID-19
epidemiology, and we have also been directing our own powerful
innovation and development engine at COVID-19," said Dr Gordon
Sanghera, CEO of Oxford Nanopore. "We designed our first nanopore
sequencing device to be used by any scientist, anywhere. Now, with
LamPORE, we want to bring the accessibility and scalability of
nanopore sequencing into the area of rapid testing."
Oxford Nanopore is collaborating with scientists in multiple
institutions for rapid optimisation and validation of the LamPORE
method for SARS-CoV-2 detection.
About LamPORE
The LamPORE method provides certain advantages in the detection
of SARS-CoV-2:
-- Simple materials for precise results: With simple hardware
requirements, LamPORE combines the established, rapid, low cost
LAMP method for initial amplification of the virus with Oxford
Nanopore sequencing for a precise, digital result.
LAMP alone has been used for the detection of virus with a
colour based readout, but interpretation of colour-based results
can be challenging at scale; sequencing provides a digital
'readout'
-- Available materials: The reagents required are low-cost and
are detached from the supply chains that currently serve RT-PCR
testing systems, where devices and reagents are in global short
supply
-- Scalability and rapid results : Scaling-up of sample numbers
is performed using molecular barcodes to run multiple samples at
the same time.
o When used on the smallest sequencing device, MinION, 96
samples can be analysed in around an hour or 1,152 samples in
around 4.5 hours. Smaller numbers can be analysed on-demand if
required
o Where there is a requirement to process much larger numbers of
samples, a single desktop GridION sequencing device allowed five
times this number (480 samples in just over an hour, or 5,760
samples in 4-5 hours), in the same timeframe
-- Sample type: The assay is being developed for compatibility with swabs or saliva samples.
-- Analysis of other pathogens: The LamPORE method also has the
potential to be developed for the simultaneous analysis of multiple
pathogens including SAR-CoV-2. This has potential utility when the
prevalence of COVID-19 has fallen, and that of other respiratory
pathogens is high, in order to screen for SARS-CoV-2 when it is
less common in a population
-ends-
Contact: media@nanoporetech.com
www.nanoporetech.com/covid19
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAPPUCUAUPUPGG
(END) Dow Jones Newswires
May 22, 2020 02:00 ET (06:00 GMT)
Ip (LSE:IPO)
Historical Stock Chart
From Apr 2024 to May 2024
Ip (LSE:IPO)
Historical Stock Chart
From May 2023 to May 2024